Innovative Peptide Solutions

# Product Data Sheet

| | |
|---|---|
| **Product:** | Antigen Peptide CD22 HLA- A*0201 (SLPYHSQKL) |
| **Product Code:** | SP-MHCI-0095 |
| **Protein ID:** | P20273 |
| **Sequence:** | H-SLPYHSQKL-OH |
| **Source:** | B-cell receptor CD22<br>Human |
| **Amount:** | 50 µg |
| **Purity:** | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
| **Binding Allel Type:** | HLA-A*02:01 |
| **Remark:** | The peptide is supplied as trifluoroacetate salt. |
| **Storage conditions:** | Store at -20°C |

**Use recommended within 6 months**

**Application protocol:** https://jpt.com/support-contact/resources/application-protocols/

Not for human use, for research purposes only

JPT Peptide Technologies GmbH
Volmerstrasse 5
12489 Berlin, Germany
T +49-30-6392-5500
peptide@jpt.com | www.jpt.com

Geschäftsführer / Managing Directors
Aurélien Claeyssen
Sean Marett
Dr. Sierk Pötting

Sitz / Registered Office Berlin
Gerichtsstand / Jurisdiction Berlin
Amtsgericht Charlottenburg
HRB 92692 B
Ust.-IdNr. / VAT-ID DE814044483

Bankverbindung / Bank Account
Deutsche Bank Berlin
Konto-Nr. / Account-No. 915 165 500
IBAN DE84 1007 0000 0915 1655 00
BIC / SWIFT DEUTDEBBXXX

TÜVRheinland CERTIFIED
Management System ISO 9001:2015
www.tuv.com ID 9105022388